Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Olivia S Costa"'
Autor:
Craig I Coleman, Olivia S Costa, William L Baker, Yuani Roman-Morillo, Kelly McNeil-Posey, Belinda Lovelace, C Michael White
Publikováno v:
BMJ Open, Vol 10, Iss 11 (2020)
Introduction As oral factor Xa (oFXa) inhibitor use has increased, so has publication of case series describing related bleeding managed with four-factor prothrombin complex concentrate (4F-PCC).Objective This review aimed to identify case series des
Externí odkaz:
https://doaj.org/article/7a0108212d01419587c416ea3c1520d4
Autor:
Olivia S. Costa, Stuart J. Connolly, Mukul Sharma, Jan Beyer-Westendorf, Mary J. Christoph, Belinda Lovelace, Craig I. Coleman
Publikováno v:
Critical Care, Vol 26, Iss 1, Pp 1-13 (2022)
Abstract Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding. Four-factor proth
Externí odkaz:
https://doaj.org/article/5a95a8a8d12246ddbc13b48e098b4962
Autor:
Craig I. Coleman, Olivia S. Costa, Stuart J. Connolly, Mukul Sharma, Jan Beyer-Westendorf, Mary J. Christoph-Schubel, Belinda Lovelace
Publikováno v:
Critical Care, Vol 27, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/4e44f0a675cb47fdb0520df4c3ddba7c
Autor:
Olivia S. Costa, Stanley Thompson, Veronica Ashton, Michael Palladino, Thomas J. Bunz, Craig I. Coleman
Publikováno v:
Thrombosis Journal, Vol 18, Iss 1, Pp 1-9 (2020)
Abstract Background African Americans are under-represented in trials evaluating oral anticoagulants for the treatment of acute venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban versus war
Externí odkaz:
https://doaj.org/article/e51d1e5c7f5d4f8bbe36ce907d2c77f3
Autor:
Timothy C. Hutcherson, Nicole E. Cieri-Hutcherson, Maggie M. Lycouras, Dharmista Koehler, Madison Mortimer, Christina J. Schaefer, Olivia S. Costa, Ashley L. Bohlmann, Mudit K. Singhal
Publikováno v:
Pharmacy, Vol 10, Iss 6, p 172 (2022)
Background: The objective of this systematic review was to characterize the efficacy and safety of evening primrose (EP) for facilitation of parturition in peripartum persons. Methods: This search sought records related to the efficacy and safety of
Externí odkaz:
https://doaj.org/article/c6063efa59444fb4a14ec6256c44ec34
Autor:
Olivia S. Costa PharmD, Jan Beyer-Westendorf MD, Veronica Ashton MPH, Dejan Milentijevic PhD, MBA, Kenneth Todd Moore MS, Thomas J. Bunz PharmD, PhD, Craig I. Coleman PharmD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
African Americans (AAs) and obese individuals have increased thrombotic risk. This study evaluated the effectiveness and safety of rivaroxaban versus warfarin in obese, AAs with nonvalvular atrial fibrillation (NVAF) or venous thromboembolism (VTE).
Externí odkaz:
https://doaj.org/article/1dacf04f817f4ecbae22ce1b2050b4fa
Autor:
Benjamin Miao, Monique Miller, Belinda Lovelace, Anne Beaubrun, Kelly McNeil-Posey, Mark J. Alberts, William Frank Peacock, Olivia S. Costa, Charles Michael White, Craig I. Coleman
Publikováno v:
TH Open, Vol 04, Iss 03, Pp e211-e217 (2020)
Introduction A paucity of contemporary data examining bleeding-related hospitalization outcomes in atrial fibrillation (AF) patients exists. Methods Adults in the Nationwide Readmissions Database (January 2016–November 2016) with AF and hospitalize
Externí odkaz:
https://doaj.org/article/f1f0633de8254ffe8a4188fa24ca9cbc
Autor:
Craig I. Coleman, Olivia S. Costa, Christopher W. Brescia, Burcu Vardar, Khaled Abdelgawwad, Lucas Hofmeister, Nitesh Sood
Publikováno v:
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 28
Background Advanced age and type 2 diabetes (T2D) are common in patients with nonvalvular atrial fibrillation (NVAF). We evaluated the impact of age on the effectiveness and safety of rivaroxaban versus warfarin in this population. Methods We analyze
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54af9ff83017396d2b754bb02e4d34fe
https://pubmed.ncbi.nlm.nih.gov/36377242
https://pubmed.ncbi.nlm.nih.gov/36377242
Autor:
Craig I Coleman, Nitesh Sood, Bridget O’Donnell, Burcu Vardar, Olivia S. Costa, Khaled Abdelgawwad, Christopher W. Brescia
Publikováno v:
Current Medical Research and Opinion. 37:1493-1500
Patients with nonvalvular atrial fibrillation (NVAF) and type 2 diabetes are at risk of kidney, limb, and ophthalmic complications. We evaluated the rate of these complications and death in patients with NVAF and type 2 diabetes prescribed rivaroxaba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c61e956dc434047afc79fdafd7cc496
https://doi.org/10.1080/03007995.2021.1947217
https://doi.org/10.1080/03007995.2021.1947217
Improving the utility of evidence synthesis for decision makers in the face of insufficient evidence
Autor:
Carolyn M. Rutter, M. Hassan Murad, Andrew R. Zullo, Meera Viswanathan, Amy Y. Tsou, Shazia Mehmood Siddique, Ethan M Balk, Jennifer S Lin, Mark Helfand, Timothy J Wilt, Celia Fiordalisi, Stephanie Chang, Brian Leas, Olivia S. Costa, Craig I Coleman, Elizabeth Stoeger, Karen A. Robinson
Publikováno v:
Journal of Clinical Epidemiology. 135:170-175
Objective : To identify and suggest strategies to make insufficient evidence ratings in systematic reviews more actionable. Study Design and Setting : A workgroup comprising members from the Evidence-Based Practice (EPC) Program of the Agency for Hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73575254d1b255826b0a653b5e5bf092
https://doi.org/10.1016/j.jclinepi.2021.02.028
https://doi.org/10.1016/j.jclinepi.2021.02.028